Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark ...

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

LTRN A May 5th press release indicated that the FDA cleared Lantern Pharma, Inc.’s (NASDAQ:LTRN) LP-184 trial in triple ...

Q1 2025 Earnings Call Transcript May 5, 2025 Operator: Welcome to BioNTech’s First Quarter 2025 Earnings Call. I would like ...

An investigational viral immunotherapy extended survival compared with standard care for patients with advanced non-small cell lung cancer who had inadequate response to immune checkpoint inhibitor ...

Cells have a mailing system of sorts. They can release tiny molecular balls, called extracellular vesicles (EVs), that ...

Recursion said it earned its latest milestone payout by identifying differentiated, oral small molecule leads against a ...

BUFFALO, N.Y. — University at Buffalo medicinal chemist David Heppner has received the 2025 Philip S. Portoghese Lectureship ...

Two new studies suggest a step toward a future where stem cells can be used to repair or prevent damage to the brain, ...

A hidden clue may explain why some mutated cells become cancerous and others don’t: how fast they divide. A new study from ...

Study data reveal how a specific sequence of cancer therapies can improve outcomes for patients with hard-to-treat lymphomas.

There is no standard of care for fibrolamellar liver cancer, no targeted therapies. But that may be changing, thanks to ...